Obesity Featured Articles

  1. Enhancing The Biosimilar Review Process 8/12/2025

    The biosimilar market is projected to reach over $100 billion in the next five years. Learn how to navigate the expanding landscape and overcome challenges in accessing key clinical information.

  2. How PIE Streamlines Biopharma And Payer Communication 8/12/2025

    Navigating pre-approval information exchange (PIE) with healthcare decision-makers is essential for market success. Learn what information can be shared and the best strategies for communication.

  3. AI-Enhanced Clinical Project Management For Cell And Gene Therapy Clinical Trials 8/12/2025

    Consultant Jessica Cordes explores two of the most critical uses of AI for cell and gene therapy clinical trials: real-time patient journey coordination and predictive enrollment. 

  4. You Just Secured $50 Million. Now On To The Hard Part: Clinical Trials 8/12/2025

    4C Associates' life sciences director Tom Wells explores common pitfalls of early-stage biotechs' transition into clinical trials and shows how early involvement of sourcing professionals can improve delivery, control spend, and help retain oversight.

  5. Hiring Your Head Of Quality - Borrow Or Build? 8/11/2025

    Leaning on an interim Head of Quality offers advantages during the search for a full-time hire, such as flexibility and access to seasoned expertise for startups.

  6. Advice For Building Clinical Trial Model That Bridge The Digital Divide 8/11/2025

    Explore the strategic use of user-friendly digital systems to enhance participant engagement and reduce errors, thereby prioritizing a culture of quality over error tolerance.

  7. From Insights To Action: The Transformative Power Of Visualization In Clinical Science 8/11/2025

    Explore the critical role of data visualization in clinical research and address the challenges of interpreting fragmented raw data to derive actionable insights that enhance patient outcomes.

  8. The Rise Of Targeted Modalities In Pharmaceutical Development 8/11/2025

    Targeted modalities are pushing the boundaries of technology and therapeutic effectiveness. Their potential to transform patient care depends on leveraging the right expertise, technologies, and partnerships.

  9. Targeted Protein Degraders: Transforming Oral Therapeutics 8/11/2025

    CDMOs play a critical role in TPD development by offering specialized infrastructure and analytical capabilities to support the transition from preclinical research to clinical supply and commercialization.

  10. Targeted Modalities: Trends, Challenges, CDMO Considerations 8/11/2025

    Targeted modalities are designed to bind specifically to receptors or biological targets, ensuring a more directed and effective treatment while reducing systemic exposure and unintended side-effects.